Certara & xybion partner to integrate nonclinical r&d software to streamline assessing drug safety & efficacy

Princeton, nj / accesswire / august 8, 2023 / xybion digital inc. (tsxv:xybn) ("xybion"), a global, low-code saas company that enables digital transformation in highly regulated labs and certara, inc. (cert), a global leader in biosimulation, announced today that they have signed a partnership agreement to bring new integrated solutions in the nonclinical r&d space with xybion's nonclinical lims-pristima® xd and certara's send explorer™, pinnacle 21™ and other software products. today's lab operations are becoming increasingly digitized.
CERT Ratings Summary
CERT Quant Ranking